The aim of this collaborative prospective real-world evidence study is to evaluate the effectiveness, patient ́s profile characterisation, patient predisposition description, treatment sequence of PARPi, and treatment beyond PARPi progression in patients with HER2-ve ABC, who have germline and/or somatic mutation in BRCA1/2 genes, or HRR genes treated with olaparib or talazoparib. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.